NCT00850642View on ClinicalTrials.gov

GSK2190915 Moderate to Severe Asthma Study

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 26, 2009

Primary Completion Date

June 2, 2010

Study Completion Date

June 2, 2010

Conditions
Asthma
Interventions
DRUG

GSK2190195 100mg

GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.

DRUG

Placebo

"Placebo :~2% (w/w) Ethanol, sucralose (5 mg/100 mL of oral solution) to 100 % (w/w) aqueous sodium carbonate buffer (0.010 M, pH 9-10)"

Trial Locations (8)

L8N 4A6

GSK Investigational Site, Hamilton

K7L 2V6

GSK Investigational Site, Kingston

H4J 1C5

GSK Investigational Site, Montreal

G1V 4G5

GSK Investigational Site, Sainte-Foy

G12 0YN

GSK Investigational Site, Glasgow

LE3 9QP

GSK Investigational Site, Leicester

NW10 7EW

GSK Investigational Site, London

M23 9QZ

GSK Investigational Site, Manchester

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY